# US 2026/0028330 A1 · Heteroaryl carboxamide and related gpr84 antagonists and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0028330 A1
- Document ID: US20260028330A1
- Status: Published application
- Kind: A1
- Application number: 18/998,656
- Filed: 2023-08-02
- Published: 2026-01-29
- Earliest claimed: 2022-08-22
- Assignees: Liminal Biosciences Limited
- Applicants: Liminal Biosciences Limited
- Inventors: Shaun Abbott; Mylène De Lèsèleuc; Julien Martel; ELYSE Bourque; Jeremy Green; Nadia Michel Nasser
- Web page: https://patentgrep.com/patent/US20260028330A1

## CPC

- C07D 405/06: linked by a carbon chain containing only aliphatic carbon atoms
- A61K 31/4025: not condensed and containing further heterocyclic rings, e.g. cromakalim
- A61K 31/4155: non condensed and containing further heterocyclic rings
- A61K 31/4178: not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A61K 31/4192: 1,2,3-Triazoles
- A61K 31/422: not condensed and containing further heterocyclic rings
- A61K 31/427: not condensed and containing further heterocyclic rings
- A61K 31/4412: having oxo groups directly attached to the heterocyclic ring
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- C07D 213/82: in position 3
- C07D 249/04: 1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 405/14: containing three or more hetero rings
- C07D 413/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 417/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of GPR84, and the treatment of GPR84-mediated disorders.

## Claims

### Claim 1

A compound of Formula I:
or a pharmaceutically acceptable salt thereof, wherein:
A1 is a 5-6 membered heteroarylene containing 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 6-membered unsaturated oxo-heterocyclylene containing 1 nitrogen atom; or phenylene; each of which is substituted with m occurrences of R3;
A2 is phenylene, a 5-6 membered heteroarylene containing 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 9-10 membered partially saturated carbocyclylene; each of which is substituted with n occurrences of R4;
L1 is a C1-6 bivalent straight or branched saturated hydrocarbon chain wherein 1 methylene unit of the chain is optionally replaced with —O—;
L2 is —C(O)N(R5)—, —N(R6)C(O)—, —N(R6)—, —N(R6)—(C1-4 alkylene)-, —(C1-4 alkylene)-N(R6)—, —S(O)2N(R5)—, —N(R6)S(O)2—, —CO2—, or —OC(O)—;
R1 is —C(O)N(R7)(R8), a 6-11 membered saturated or partially unsaturated, bridged or spirocyclic, bicyclic heterocyclic ring containing 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring containing 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein each of said bicyclic heterocyclic ring and monocyclic heterocyclic ring are substituted with q instances of R9;
R2 is —(C2-4 alkynylene)-(C3-7 cycloalkyl) or hydrogen;
R3 represents independently for each occurrence C1-6 alkyl or halo;
R4 represents independently for each occurrence C1-6 alkyl, halo, hydroxyl, C1-6 alkoxyl, C3-6 cycloalkyl, or —N(R7)(R8);
R5 is C1-6 alkyl, C3-6 cycloalkyl, or hydrogen; or R5 and one occurrence of R4 are taken together with their intervening atoms to form a 5-6 membered ring containing 1 nitrogen atom;
R6 is C1-6 alkyl, C3-6 cycloalkyl, or hydrogen;
R7 and R8 each represent independently for each occurrence hydrogen, C1-6 alkyl, or C3-6 cycloalkyl; or R7 and R8 are taken together with the nitrogen atom to which they are attached to form a 3-7 membered heterocyclic ring containing 1 nitrogen atom;
R9 represents independently for each occurrence C1-6 alkyl, halo, hydroxyl, C1-6 alkoxyl, or C3-6 cycloalkyl; and
m, n, and q are independently 0, 1, or 2;
wherein if R1, L1, A1 and L2 taken together form
then n is 1 or 2, and R4 represents independently for each occurrence halo, hydroxyl, C1-6 alkoxyl, C3-6 cycloalkyl, or —N(R7)(R8).

### Claim 2 (depends on 1)

The compound of claim 1, wherein the compound is a compound of Formula I.

### Claim 3 (depends on 1, 2)

The compound of claim 1 or 2, wherein A1 is a 5-6 membered heteroarylene containing 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein the heteroarylene is substituted with m occurrences of R3.

### Claim 4 (depends on 1, 2)

The compound of claim 1 or 2, wherein A1 is 1,2,3-triazolylene, imidazolylene, pyrrolylene, pyrazolylene, oxazolylene, thiazolylene, or pyridinylene, each of which is substituted with m occurrences of R3.

### Claim 5 (depends on 1, 2)

The compound of claim 1 or 2, wherein A1 is 1,2,3-triazolylene substituted with m occurrences of R3.

### Claim 6 (depends on 1, 2)

The compound of claim 1 or 2, wherein A1 is a 6-membered unsaturated oxo-heterocyclylene containing 1 nitrogen atom; wherein the oxo-heterocyclylene is substituted with m occurrences of R3.

### Claim 7 (depends on 1, 2)

The compound of claim 1 or 2, wherein A1 is
which is substituted with m occurrences of R3.

### Claim 8 (depends on 1, 2)

The compound of claim 1 or 2, wherein A1 is phenylene substituted with m occurrences of R3.

### Claim 9 (depends on 1, 2)

The compound of claim 1 or 2, wherein A1 is
substituted with m occurrences of R3.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The compound of any one of claims 1-9, wherein m is 1.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The compound of any one of claims 1-9, wherein m is 0.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The compound of any one of claims 1-11, wherein L2 is —C(O)N(R5)—.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The compound of any one of claims 1-11, wherein L2 is —N(R6)C(O)—.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The compound of any one of claims 1-11, wherein L2 is —N(R6)—.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The compound of any one of claims 1-11, wherein L2 is —N(R6)—(C1-4 alkylene)- or —(C1-4 alkylene)-N(R6)—.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The compound of any one of claims 1-12, wherein R5 is C1-6 alkyl.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The compound of any one of claims 1-12, wherein R5 is methyl.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The compound of any one of claims 1-12, wherein R5 is C3-6 cycloalkyl.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The compound of any one of claims 1-12, wherein R5 is cyclopropyl.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The compound of any one of claims 1-12, wherein R5 is hydrogen.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The compound of any one of claims 1-12, wherein R5 and one occurrence of R4 are taken together with their intervening atoms to form a 5-6 membered ring containing 1 nitrogen atom.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 14, 15)

The compound of any one of claims 1-11 or 13-15, wherein R6 is C1-6 alkyl.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 14, 15)

The compound of any one of claims 1-11 or 13-15, wherein R6 is methyl.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 14, 15)

The compound of any one of claims 1-11 or 13-15, wherein R6 is hydrogen.

### Claim 25 (depends on 1)

The compound of claim 1, wherein the compound is of formulae I-a or I-b, or a pharmaceutically acceptable salt thereof:

### Claim 26 (depends on 1)

The compound of claim 1, wherein the compound is of formulae I-c or I-d, or a pharmaceutically acceptable salt thereof:

### Claim 27 (depends on 1)

The compound of claim 1, wherein the compound is any one of formulae I-e, I-f, I-g, I-h, I-i, or I-j, or a pharmaceutically acceptable salt thereof:

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The compound of any one of claims 1-27, wherein R1 is —C(O)N(R7)(R8).

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The compound of any one of claims 1-28, wherein R7 and R8 are independently C1-6 alkyl.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The compound of any one of claims 1-27, wherein R1 is a 6-11 membered saturated or partially unsaturated, bridged or spirocyclic, bicyclic heterocyclic ring containing 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein the bicyclic heterocyclic ring is substituted with q instances of R9.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The compound of any one of claims 1-27, wherein R1 is
substituted with q instances of R9.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 30)

The compound of any one of claims 1-27, 30, or 31, wherein q is 0.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The compound of any one of claims 1-32, wherein R2 is —(C2-4 alkynylene)-(C3-7 cycloalkyl).

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The compound of any one of claims 1-32, wherein R2 is —(C≡C)—(C3-5 cycloalkyl).

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The compound of any one of claims 1-32, wherein R2 is —(C≡C)-(cyclopropyl).

### Claim 36 (depends on 1)

The compound of claim 1, wherein the compound is of formulae I-k or I-l, or a pharmaceutically acceptable salt thereof:

### Claim 37 (depends on 1)

The compound of claim 1, wherein the compound is of formulae I-m or I-n, or a pharmaceutically acceptable salt thereof:

### Claim 38 (depends on 1)

The compound of claim 1, wherein the compound is any one of formulae I-o, I-p, I-q, I-r, I-s, or I-t, or a pharmaceutically acceptable salt thereof:

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The compound of any one of claims 1-38, wherein A2 is phenylene substituted with n occurrences of R4.

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The compound of any one of claims 1-38, wherein A2 is
substituted with n occurrences of R4.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The compound of any one of claims 1-38, wherein A2 is a 5-6 membered heteroarylene containing 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein the heteroarylene is substituted with n occurrences of R4.

### Claim 42 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The compound of any one of claims 1-38, wherein A2 is pyridinylene substituted with n occurrences of R4.

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The compound of any one of claims 1-38, wherein A2 is a 9-10 membered partially saturated carbocyclylene substituted with n occurrences of R4.

### Claim 44 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The compound of any one of claims 1-35, wherein A is
each of which is substituted with n occurrences of R4, wherein ** is the point of attachment to R2.

### Claim 45 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The compound of any one of claims 1-44, wherein R4 represents independently for each occurrence C1-6 alkyl or halo.

### Claim 46 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The compound of any one of claims 1-44, wherein R4 represents independently for each occurrence methyl, fluoro, chloro, or bromo.

### Claim 47 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The compound of any one of claims 1-44, wherein R4 is methyl.

### Claim 48 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

The compound of any one of claims 1-47, wherein n is 1.

### Claim 49 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

The compound of any one of claims 1-47, wherein n is 2.

### Claim 50 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49)

The compound of any one of claims 1-49, wherein L1 is a C1-6 bivalent straight or branched saturated hydrocarbon chain.

### Claim 51 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49)

The compound of any one of claims 1-49, wherein L1 is —CH2—.

### Claim 52 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49)

The compound of any one of claims 1-49, wherein L1 is —CH2—O—.

### Claim 53

A compound in Table 1, or a pharmaceutically acceptable salt thereof.

### Claim 54 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53)

A pharmaceutical composition comprising a compound according to any one of claims 1-53 and a pharmaceutically acceptable carrier.

### Claim 55 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53)

A method of inhibiting a GPR84, comprising contacting a GPR84 with an effective amount of a compound of any one of claims 1-53 to inhibit the GPR84.

### Claim 56 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53)

A method of treating a GPR84-mediated disorder, disease, or condition in a patient, comprising administering to said patient in need thereof a therapeutically effective amount of a compound of any one of claims 1-53.

### Claim 57 (depends on 56)

The method of claim 56, wherein the disorder, disease, or condition is a proliferative disorder, a fibrotic disease, an infectious disease, an autoimmune disease, an endocrine and/or metabolic disease, a cardiovascular disease, a disease involving impairment of immune cell function, a neuroinflammatory condition, a neurodegenerative condition, an inflammatory condition, multiple sclerosis, or pain.

### Claim 58 (depends on 56)

The method of claim 56, wherein the disorder, disease, or condition is cancer.

### Claim 59 (depends on 58)

The method of claim 58, wherein the cancer is leukemia or hepatocellular carcinoma (HCC).

### Claim 60 (depends on 58)

The method of claim 58, wherein the cancer is acute myeloid leukemia (AML).

### Claim 61 (depends on 56)

The method of claim 56, wherein the disorder, disease, or condition is a proliferative disorder associated with one or more activating mutations in GPR84.

### Claim 62 (depends on 56)

The method of claim 56, wherein the disorder, disease, or condition is a chronic viral infection.

### Claim 63 (depends on 56)

The method of claim 56, wherein the disorder, disease, or condition is an inflammatory condition selected from rheumatoid arthritis, chronic obstructive pulmonary disease, asthma, idiopathic pulmonary fibrosis (IPF), psoriasis, Crohn's disease, ulcerative colitis, uveitis, periodontitis, esophagitis, gastroesophageal reflux disease (GERD), inflammatory bowel disease, or pyoderma gangrenosum.

### Claim 64 (depends on 56)

The method of claim 56, wherein the disorder, disease, or condition is nonalcoholic steatohepatitis (NASH) or idiopathic pulmonary fibrosis (IPF).

### Claim 65 (depends on 56)

The method of claim 56, wherein the disorder, disease, or condition is systemic lupus erythmatosus (SLE).

### Claim 66 (depends on 56)

The method of claim 56, wherein the disorder, disease, or condition is neuropathic pain.

### Claim 67 (depends on 56)

The method of claim 56, wherein the disorder, disease, or condition is Alzheimer's disease.

### Claim 68 (depends on 56)

The method of claim 56, wherein the disorder, disease, or condition is idiopathic pulmonary fibrosis (IPF).

### Claim 69 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53)

A method of increasing the efficacy of vaccination in a patient, comprising administering to said patient in need thereof a compound of any one of claims 1-53 as an adjuvant.

### Claim 70

A compound of Formula II:
or a pharmaceutically acceptable salt thereof, wherein:
A1 is a 5-6 membered heteroarylene containing 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; a 6-membered unsaturated oxo-heterocyclylene containing 1 nitrogen atom; or phenylene; each of which is substituted with m occurrences of R3;
A2 is phenylene, a 5-6 membered heteroarylene containing 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 9-10 membered partially saturated carbocyclylene; each of which is substituted with n occurrences of R4;
L1 is a C1-6 bivalent straight or branched saturated hydrocarbon chain wherein 1 methylene unit of the chain is optionally replaced with —O—;
L2 is —C(O)N(R5)—, —N(R6)C(O)—, —N(R6)—, —N(R6)—(C1-4 alkylene)-, —(C1-4 alkylene)-N(R6)—, —S(O)2N(R5)—, —N(R6)S(O)2—, —CO2—, —OC(O)—, —C(O—C1-4 alkyl)=N—, or -(4-5 membered saturated monocyclic heterocyclylene containing 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur)-N(C1-4 alkyl)-;
R1 is —C(O)N(R7)(R8), a 6-11 membered saturated or partially unsaturated, bridged or spirocyclic, bicyclic heterocyclic ring containing 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring containing 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein each of said bicyclic heterocyclic ring and monocyclic heterocyclic ring are substituted with q instances of R9;
R2 is —(C2-4 alkynylene)-(C3-7 cycloalkyl) or hydrogen;
R3 represents independently for each occurrence C1-6 alkyl or halo;
R4 represents independently for each occurrence C1-6 alkyl, halo, hydroxyl, C1-6 alkoxyl, C3-6 cycloalkyl, or —N(R7)(R8);
R5 is C1-6 alkyl, C3-6 cycloalkyl, or hydrogen; or R5 and one occurrence of R4 are taken together with their intervening atoms to form a 5-6 membered ring containing 1 nitrogen atom;
R6 is C1-6 alkyl, C3-6 cycloalkyl, or hydrogen;
R7 and R8 each represent independently for each occurrence hydrogen, C1-6 alkyl, or C3-6 cycloalkyl; or R7 and R8 are taken together with the nitrogen atom to which they are attached to form a 3-7 membered heterocyclic ring containing 1 nitrogen atom;
R9 represents independently for each occurrence C1-6 alkyl, halo, hydroxyl, C1-6 alkoxyl, or C3-6 cycloalkyl; and
m, n, and q are independently 0, 1, or 2;
wherein if R1, L1, A1 and L2 taken together form
then n is 1 or 2, and R4 represents independently for each occurrence halo, hydroxyl, C1-6 alkoxyl, C3-6 cycloalkyl, or —N(R7)(R8).

### Claim 71 (depends on 70)

The compound of claim 70, wherein the compound is a compound of Formula II.

### Claim 72 (depends on 70, 71)

The compound of claim 70 or 71, wherein A1 is a 5-6 membered heteroarylene containing 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein the heteroarylene is substituted with m occurrences of R3.

### Claim 73 (depends on 70, 71)

The compound of claim 70 or 71, wherein A1 is 1,2,3-triazolylene, imidazolylene, pyrrolylene, pyrazolylene, oxazolylene, thiazolylene, or pyridinylene, each of which is substituted with m occurrences of R3.

### Claim 74 (depends on 70, 71)

The compound of claim 70 or 71, wherein A1 is 1,2,3-triazolylene substituted with m occurrences of R3.

### Claim 75 (depends on 70, 71)

The compound of claim 70 or 71, wherein A1 is a 6-membered unsaturated oxo-heterocyclylene containing 1 nitrogen atom; wherein the oxo-heterocyclylene is substituted with m occurrences of R3.

### Claim 76 (depends on 70, 71)

The compound of claim 70 or 71, wherein A1 is
which is substituted with m occurrences of R3.

### Claim 77 (depends on 1, 2)

The compound of claim 1 or 2, wherein A1 is phenylene substituted with m occurrences of R3.

### Claim 78 (depends on 70, 71)

The compound of claim 70 or 71, wherein A1 is
substituted with m occurrences of R3.

### Claim 79 (depends on 70, 71, 72, 73, 74, 75, 76, 77, 78)

The compound of any one of claims 70-78, wherein m is 1.

### Claim 80 (depends on 70, 71, 72, 73, 74, 75, 76, 77, 78)

The compound of any one of claims 70-78, wherein m is 0.

### Claim 81 (depends on 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80)

The compound of any one of claims 70-80, wherein L2 is —C(O)N(R5)—.

### Claim 82 (depends on 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80)

The compound of any one of claims 70-80, wherein L2 is —N(R6)C(O)—.

### Claim 83 (depends on 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80)

The compound of any one of claims 70-80, wherein L2 is —N(R6)—.

### Claim 84 (depends on 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80)

The compound of any one of claims 70-80, wherein L2 is —N(R6)—(C1-4 alkylene)- or —(C1-4 alkylene)-N(R6)—.

### Claim 85 (depends on 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81)

The compound of any one of claims 70-81, wherein R5 is C1-6 alkyl.

### Claim 86 (depends on 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81)

The compound of any one of claims 70-81, wherein R5 is methyl.

### Claim 87 (depends on 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81)

The compound of any one of claims 70-81, wherein R5 is C3-6 cycloalkyl.

### Claim 88 (depends on 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81)

The compound of any one of claims 70-81, wherein R5 is cyclopropyl.

### Claim 89 (depends on 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81)

The compound of any one of claims 70-81, wherein R5 is hydrogen.

### Claim 90 (depends on 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81)

The compound of any one of claims 70-81, wherein R5 and one occurrence of R4 are taken together with their intervening atoms to form a 5-6 membered ring containing 1 nitrogen atom.

### Claim 91 (depends on 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83)

The compound of any one of claims 70-80 or 81-83, wherein R6 is C1-6 alkyl.

### Claim 92 (depends on 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83)

The compound of any one of claims 70-80 or 81-83, wherein R6 is methyl.

### Claim 93 (depends on 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83)

The compound of any one of claims 70-80 or 81-83, wherein R6 is hydrogen.

### Claim 94 (depends on 70)

The compound of claim 70, wherein the compound is of formulae II-a, II-b, or II-a-1, or a pharmaceutically acceptable salt thereof:

### Claim 95 (depends on 70)

The compound of claim 70, wherein the compound is of formulae II-c or II-d, or a pharmaceutically acceptable salt thereof:

### Claim 96 (depends on 70)

The compound of claim 70, wherein the compound is any one of formulae II-e, II-f, II-g, II-h, II-i, or II-j, or a pharmaceutically acceptable salt thereof:

### Claim 97 (depends on 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96)

The compound of any one of claims 70-96, wherein R1 is —C(O)N(R7)(R8).

### Claim 98 (depends on 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97)

The compound of any one of claims 70-97, wherein R7 and R8 are independently C1-6 alkyl.

### Claim 99 (depends on 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96)

The compound of any one of claims 70-96, wherein R1 is a 6-11 membered saturated or partially unsaturated, bridged or spirocyclic, bicyclic heterocyclic ring containing 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; wherein the bicyclic heterocyclic ring is substituted with q instances of R9.

### Claim 100 (depends on 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96)

The compound of any one of claims 70-96, wherein R1 is
substituted with q instances of R9.

### Claim 101 (depends on 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 99)

The compound of any one of claims 70-96, 99, or 100, wherein q is 0.

### Claim 102 (depends on 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101)

The compound of any one of claims 70-101, wherein R2 is —(C2-4 alkynylene)-(C3-7 cycloalkyl).

### Claim 103 (depends on 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101)

The compound of any one of claims 70-101, wherein R2 is —(C≡C)—(C3-5 cycloalkyl).

### Claim 104 (depends on 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101)

The compound of any one of claims 70-101, wherein R2 is —(C≡C)-(cyclopropyl).

### Claim 105 (depends on 70)

The compound of claim 70, wherein the compound is of formulae II-k, II-l, or II-k-1, or a pharmaceutically acceptable salt thereof:

### Claim 106 (depends on 70)

The compound of claim 70, wherein the compound is of formulae II-m or II-n, or a pharmaceutically acceptable salt thereof:

### Claim 107 (depends on 70)

The compound of claim 70, wherein the compound is any one of formulae II-o, II-p, II-q, II-r, II-s, or II-t, or a pharmaceutically acceptable salt thereof:

### Claim 108 (depends on 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107)

The compound of any one of claims 70-107, wherein A2 is phenylene substituted with n occurrences of R4.

### Claim 109 (depends on 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107)

The compound of any one of claims 70-107, wherein A2 is
substituted with n occurrences of R4.

### Claim 110 (depends on 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107)

The compound of any one of claims 70-107, wherein A2 is a 5-6 membered heteroarylene containing 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein the heteroarylene is substituted with n occurrences of R4.

### Claim 111 (depends on 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107)

The compound of any one of claims 70-107, wherein A2 is pyridinylene substituted with n occurrences of R4.

### Claim 112 (depends on 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107)

The compound of any one of claims 70-107, wherein A2 is a 9-10 membered partially saturated carbocyclylene substituted with n occurrences of R4.

### Claim 113 (depends on 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104)

The compound of any one of claims 70-104, wherein A2 is
each of which is substituted with n occurrences of R4, wherein ** is the point of attachment to R2.

### Claim 114 (depends on 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113)

The compound of any one of claims 70-113, wherein R4 represents independently for each occurrence C1-6 alkyl or halo.

### Claim 115 (depends on 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113)

The compound of any one of claims 70-113, wherein R4 represents independently for each occurrence methyl, fluoro, chloro, or bromo.

### Claim 116 (depends on 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113)

The compound of any one of claims 70-113, wherein R4 is methyl.

### Claim 117 (depends on 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116)

The compound of any one of claims 70-116, wherein n is 1.

### Claim 118 (depends on 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116)

The compound of any one of claims 70-116, wherein n is 2.

### Claim 119 (depends on 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118)

The compound of any one of claims 70-118, wherein L1 is a C1-6 bivalent straight or branched saturated hydrocarbon chain.

### Claim 120 (depends on 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118)

The compound of any one of claims 70-118, wherein L1 is —CH2—.

### Claim 121 (depends on 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118)

The compound of any one of claims 70-118, wherein L1 is —CH2—O—.

### Claim 122

A compound in Table 1A, or a pharmaceutically acceptable salt thereof.

### Claim 123 (depends on 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122)

A pharmaceutical composition comprising a compound according to any one of claims 70-122 and a pharmaceutically acceptable carrier.

### Claim 124 (depends on 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122)

A method of inhibiting a GPR84, comprising contacting a GPR84 with an effective amount of a compound of any one of claims 70-122 to inhibit the GPR84.

### Claim 125 (depends on 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122)

A method of treating a GPR84-mediated disorder, disease, or condition in a patient, comprising administering to said patient in need thereof a therapeutically effective amount of a compound of any one of claims 70-122.

### Claim 126 (depends on 125)

The method of claim 125, wherein the disorder, disease, or condition is a proliferative disorder, a fibrotic disease, an infectious disease, an autoimmune disease, an endocrine and/or metabolic disease, a cardiovascular disease, a disease involving impairment of immune cell function, a neuroinflammatory condition, a neurodegenerative condition, an inflammatory condition, multiple sclerosis, or pain.

### Claim 127 (depends on 125)

The method of claim 125, wherein the disorder, disease, or condition is cancer.

### Claim 128 (depends on 127)

The method of claim 127, wherein the cancer is leukemia or hepatocellular carcinoma (HCC).

### Claim 129 (depends on 127)

The method of claim 127, wherein the cancer is acute myeloid leukemia (AML).

### Claim 130 (depends on 125)

The method of claim 125, wherein the disorder, disease, or condition is a proliferative disorder associated with one or more activating mutations in GPR84.

### Claim 131 (depends on 125)

The method of claim 125, wherein the disorder, disease, or condition is a chronic viral infection.

### Claim 132 (depends on 125)

The method of claim 125, wherein the disorder, disease, or condition is an inflammatory condition selected from rheumatoid arthritis, chronic obstructive pulmonary disease, asthma, idiopathic pulmonary fibrosis (IPF), psoriasis, Crohn's disease, ulcerative colitis, uveitis, periodontitis, esophagitis, gastroesophageal reflux disease (GERD), inflammatory bowel disease, or pyoderma gangrenosum.

### Claim 133 (depends on 125)

The method of claim 125, wherein the disorder, disease, or condition is nonalcoholic steatohepatitis (NASH) or idiopathic pulmonary fibrosis (IPF).

### Claim 134 (depends on 125)

The method of claim 125, wherein the disorder, disease, or condition is systemic lupus erythmatosus (SLE).

### Claim 135 (depends on 125)

The method of claim 125, wherein the disorder, disease, or condition is neuropathic pain.

### Claim 136 (depends on 125)

The method of claim 125, wherein the disorder, disease, or condition is Alzheimer's disease.

### Claim 137 (depends on 125)

The method of claim 125, wherein the disorder, disease, or condition is idiopathic pulmonary fibrosis (IPF).

### Claim 138 (depends on 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122)

A method of increasing the efficacy of vaccination in a patient, comprising administering to said patient in need thereof a compound of any one of claims 70-122 as an adjuvant.
